Trial Profile
A Double-Blind, Placebo-Controlled, Crossover, Flexible-Dose Evaluation of the Efficacy, Safety and Tolerability of STX209 in the Treatment of Irritability in Subjects With Fragile X Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2014
Price :
$35
*
At a glance
- Drugs Arbaclofen (Primary)
- Indications Fragile X syndrome
- Focus Therapeutic Use
- Sponsors Seaside Therapeutics
- 31 Oct 2014 New trial record